Bone Marrow Examination Can Predict Progression Of Multiple Myeloma
A recent European study found that the percentage of plasma cells detected in a bone marrow sample is a strong predictor of multiple myeloma progression following stem cell transplantation. Although...
View ArticlePat’s Place: How Much Does A Multiple Myeloma Patient Need To Know About...
The days of a cancer patient blindly following the doctor’s orders and rarely getting a second opinion are over. For multiple myeloma, there aren’t just one or two standard treatment options. Instead,...
View ArticleRevlimid Cancer Controversy Flares
Several investment bank reports published this week have heightened concern about a potential link between Revlimid and second cancers in multiple myeloma patients. The reports have unnerved investors...
View ArticleRevlimid Dosing To Continue In CALGB Maintenance Trial
The Myeloma Beacon has learned that the Cancer and Leukemia Group B, the cooperative group running the CALGB / ECOG / BMT-CTN 100104 Revlimid maintenance trial, currently has no plans to halt Revlimid...
View ArticleRandomized Clinical Trials: A Multiple Myeloma Patient’s Viewpoint
Adults with cancer enter clinical trials at a dismal rate of 3 percent or less, with even lower participation among minority populations. To improve this absurdly low number it is time that we look at...
View ArticleBeacon NewsFlashes – February 7, 2011
Opinion: A Multiple Myeloma Patient’s Viewpoint On Randomized Clinical Trials – In the latest article published in the opinion section of The Myeloma Beacon, Dr. Jim Omel, a physician and multiple...
View ArticleArnie’s Rebounding World: A Journey From Diagnosis To Relapse And Beyond
In March of 2006, I was 47 years old and thought I was on top of my game. I had a busy, thriving Ear, Nose, and Throat medical practice and a great wife and two kids, one in 8th grade and one in 5th. I...
View ArticleSplit May Be Emerging Regarding Long-Term Revlimid Use
A split may be developing in the multiple myeloma research community regarding the treatment implications of a possible link between long-term Revlimid use and secondary cancers. Many researchers are...
View ArticlePat’s Place: Communication With Your Physician Is Key—Patient Suggestions And...
This week I’d like to discuss two questions that patients often have: Is it OK to suggest a change in a treatment plan due to side effects, trends in numbers, or having learned about a better therapy...
View ArticlePrognosis For Multiple Myeloma Patients With Chromosomal Abnormality t(4;14)...
Results of a recent French study show that multiple myeloma patients with the chromosomal abnormality t(4;14) have a high response rate after stem cell transplantation, but continue to have poor...
View ArticleBeacon NewsFlashes – February 14, 2011
Bafetinib May Prevent Bone Loss For Cancer Patients – A series of preclinical studies indicate that the drug bafetinib (INNO-406) inhibits bone deterioration in cancer patients who are at high risk for...
View ArticleMyeloma Working Group Postpones Statement On Revlimid’s Potential Link To...
After a week of discussions about the potential link between Revlimid maintenance therapy and second cancers, the members of the International Myeloma Working Group have decided that more information...
View ArticleVariations In Nervous System Genes May Put Multiple Myeloma Patients At...
An international group of myeloma researchers has recently identified five genetic variations that may be associated with an increased risk of developing thalidomide-related peripheral neuropathy....
View ArticlePat’s Place: Common Traits Among Long-Lived Multiple Myeloma Survivors
The media often does stories about people who have lived at least one hundred years. What is their secret? Are these centenarians—as they are called—simply lucky, or do they share commonalities that...
View ArticleNew Advances In Myeloma Vaccines – Part 1: Introduction
This article is the first in a five-part series about emerging vaccines for multiple myeloma. It provides an introduction to the concept of a myeloma vaccine. The second article provides an...
View ArticleThought Leader Perspective: Dr. Kenneth Anderson On Treating Multiple Myeloma
Dr. Kenneth Anderson is a multiple myeloma thought leader, physician and researcher at Dana-Farber Cancer Institute, where he is Director of the Jerome Lipper Multiple Myeloma Center. He also is the...
View ArticlePat’s Cracked Cup: Movie Therapy
Someone recently joked that films should come with warning labels, such as “Beware, this movie features people with cancer who die in the end.” Sometimes light humorous entertainment is the best...
View ArticleNew Advances In Myeloma Vaccines – Part 2: Types Of Potential Myeloma...
This article is the second in a five-part series about emerging vaccines for multiple myeloma. It provides an introduction to the various types of vaccines that are currently under development for...
View ArticlePat’s Place: What Can Long-Lived Multiple Myeloma Survivors Teach Us?
Last week I shared a list of traits long-lived multiple myeloma survivors—those of us fortunate enough to have lived ten years or longer after our myeloma became active—tend to have in common. The...
View ArticleFirst Day Of Stem Cell Collection For Myeloma Patients Predicts Likelihood Of...
The number of stem cells harvested from multiple myeloma patients during the first day of collection predicts the success of the entire collection procedure, according to a recent study. Those...
View Article